Micro-Dosing Immunotherapy: A Path Toward Accessible Cancer Treatment

The field of immuno-oncology is undergoing a significant transformation as researchers shift focus from high-dose, expensive therapies to innovative micro-dosing protocols. Historically, cancer treatments such as CAR T-cell therapies and checkpoint inhibitors have been defined by intensive, high-cost approaches that are often inaccessible to patients outside of wealthy nations due to complex logistics and prohibitive pricing. A new movement, gaining traction in regions like Cape Town and Bangalore, explores the use of lower-intensity, fractionated dosing to stimulate the immune system more sustainably. By reducing the physical and financial burden of traditional treatments, this emerging approach seeks to address the global cost-access paradox in oncology. Proponents believe that micro-dosing could democratize life-saving care, offering a scalable solution that bridges the equity gap for millions of patients currently excluded from the biotech revolution. This shift represents a promising evolution toward more equitable cancer care delivery, potentially turning high-end immunotherapies into manageable, widely available medical interventions that can be deployed effectively on a global scale.